Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021-Reference-Cited by-同舟云学术

Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021

Published:2022-12 Issue:12 Volume:10 Page:e1807-e1814
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Mirzoev Azamdzhon,Macklin Grace R,Zhang Yiting,Mainou Bernardo A,Sadykova Umeda,Olsavszky Victor Stefan,Huseynov Shahin,Ruziev Murodali,Saidzoda Faizali,Bobokhonova Mahtob,Mach Ondrej

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria;Burns;J Virol,2013

2. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication;Minor;Vaccine,2009

3. Vaccine-derived polioviruses and the endgame strategy for global polio eradication;Kew;Annu Rev Microbiol,2005

4. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame;Parker;Expert Rev Vaccines,2015

5. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccine;Macklin;Science,2020

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Qualitative real-time RT-PCR assay for nOPV2 poliovirus detection;Journal of Virological Methods;2024-09

2. Detection of Polioviruses Type 2 among Migrant Children Arriving to the Russian Federation from a Country with a Registered Poliomyelitis Outbreak;Vaccines;2024-06-28

3. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study;The Lancet Infectious Diseases;2024-04

4. The oral poliovirus vaccine—a solution and a concern for eradication;The Lancet Infectious Diseases;2024-04

5. Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study;The Lancet Infectious Diseases;2024-04